Physician profile
Parrish Harless
NPI 1265780340
$3,954.25
in general payments reported to CMS, 2019-2025
11 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $908 · 2022: $918 · 2023: $931 · 2024: $666 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Education: $16.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.64 |
| Education | $16.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,663.90 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $855.36 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $479.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $287.83 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $144.39 | 2023-2025 | Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Braeburn INC. | $115.89 | 2024-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $95.33 | 2024 | Ingrezza |
| Indivior INC. | $47.19 | 2024-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $15.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parrish Harless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.